齐拉西酮与利培酮治疗精神分裂症对照研究

目的 探讨齐拉西酮与利培酮治疗精神分裂症患者的临床疗效及安全性.方法 将76例精神分裂症患者随机分为两组,每组38例,齐拉西酮组口服齐拉西酮治疗,利培酮组口服利培酮治疗,观察8周.于治疗前及治疗第2周、4周、6周、8周末采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应.结果 治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降(P＜0.05或0.01),同期两组评分差异均无显著性(P＞0.05);治疗8周末,齐拉西酮组有效率84.2%,利培酮组为81.6%,两组差异无显著性(P＞0.05).两组不良反应均轻微,齐拉西酮组锥体外系反应、体重增加不良反应发生率均显著低于利培酮组(P＜0.05或0.01).结论 齐拉西酮与利培酮治疗精神分裂症疗效显著且相当,但齐拉西酮引起锥体外系反应及体重增加发生率低,安全性更高、依从性更好.

A control study of ziprasidone vs.risperidone in the treatment of schizophrenia

Objective To explore the efficay and safety of ziprasidone and risperidone in the treatment of schizophrenia. Methods Seventy-six schizophrenics were randomly divided into two groups of 38 patients each, ziprasidone group took orally ziprasidone and risperidone group did risperidone for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reacnons wire the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 2nd , 4th, 6th and 8th week. Resuits After treatment, the total and each factor score of the PANSS in both groups lowered more significantly compared with pretreatment （P〈0.05 or 0. 01） , group comparisons didn＇t show significant differences in corresponding period （P〈0.05）. At the end of the 8th week, the effective rate had no significant diffrence （ziprasidone 84.2% vs. risperidone 81.6%,P〉0.05）. Adverse reactions of both groups were mild, incidences of extrapyramidal system reactions and weight gain were significantly lower in therisperidone than in ziprasidone group （P〈0.05 or 0.01）. Conclusion Ziprasidone has an evident effect equivalent to risperidone in the treatment of schizophrenia, but lower incidences of extrapyramidal system reactions and weight gain,higher safety and better compliance.